Objective Lung cancer is the most common cancer fatality in Europe (335000 deaths/yr). Non-small cell lung cancer (NSCLC) consists 85% of the cases, with 5 yr survival <15%. Hence, this proposal focuses on the urgent need for better NSCLC therapies. This is a European problem at societal and scientific level: better therapies are needed to keep the spiralling costs of European health systems under control, and the required expertise (basic science, clinical, biotech, experimental therapeutics) is scattered over the EU. Because of the diversity of the NSCLC problem (and the small/medium size of the project) we are focusing on two particular problems: 1) to find solutions for the currently clinically observed resistance problems with epidermal growth factor receptor (EGFR) targeting therapies (10% of NSCLC patients), and 2) to find a solution for the clinically unmet need for NSCLC patients with KRAS mutations (30% of NSCLC), for whom there virtually is no cure (besides very modest effects of platinum based therapies). Based on this focus, we assembled an EU wide consortium which joins excellent expertise at both the basic science (EGFR family, KRAS), clinical (involvement of several clinical study leaders) and biotech level (involvement of academic and SME biotech component). We aim:1) To identify novel drug targets for the improvement of EGFR targeting therapies and for the development of therapies for K-Ras mutant patients (via genome wide RNAi screening and kinome/secretome profiling).2) To validate these targets in innovative mouse models that replicate the clinical problem, and in patient materials (tissue and serum)3) To develop novel therapeutics based on the unique expertise of our partners: anti-receptor DARPins (designed ankyrin repeat proteins), monoclonals or soluble receptors targeting the BROADER EGFR family (to block compensatory signalling), and protein kinase inhibitorsThe results will have important basic scientific, clinical and economic impact Fields of science medical and health sciencesclinical medicineoncologylung cancernatural scienceschemical sciencesinorganic chemistrytransition metalsnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsnatural sciencesbiological sciencesgeneticsmutationnatural sciencesbiological sciencesgeneticsgenomes Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Topic(s) HEALTH.2010.2.4.1-6 - Translational research on cancers with poor prognosis. FP7-HEALTH-2010-two-stage Call for proposal FP7-HEALTH-2010-two-stage See other projects for this call Funding Scheme CP-FP - Small or medium-scale focused research project Coordinator KATHOLIEKE UNIVERSITEIT LEUVEN EU contribution € 595 504,00 Address OUDE MARKT 13 3000 Leuven Belgium See on map Region Vlaams Gewest Prov. Vlaams-Brabant Arr. Leuven Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (9) Sort alphabetically Sort by EU Contribution Expand all Collapse all IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE United Kingdom EU contribution € 357 614,00 Address SOUTH KENSINGTON CAMPUS EXHIBITION ROAD SW7 2AZ LONDON See on map Region London Inner London — West Westminster Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Total cost No data FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III Spain EU contribution € 258 564,00 Address C MELCHOR FERNANDEZ ALMAGRO 3 28029 Madrid See on map Region Comunidad de Madrid Comunidad de Madrid Madrid Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Total cost No data MARTIN-LUTHER-UNIVERSITAT HALLE-WITTENBERG Germany EU contribution € 188 112,95 Address UNIVERSITATSPLATZ 10 6108 Halle See on map Region Baden-Württemberg Stuttgart Stuttgart, Stadtkreis Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Total cost No data CANCER RESEARCH UK LBG United Kingdom EU contribution € 379 055,00 Address 2 Redman Place E20 1JQ LONDON See on map Region London Inner London — West Camden and City of London Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Total cost No data University of Zurich Switzerland EU contribution € 439 688,00 Address RAMISTRASSE 71 8006 ZURICH See on map Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Total cost No data WEIZMANN INSTITUTE OF SCIENCE Israel EU contribution € 269 838,00 Address HERZL STREET 234 7610001 Rehovot See on map Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Total cost No data VICHEM CHEMIE KUTATO KORLATOLT FELELOSSEGU TARSASAG Hungary EU contribution € 201 875,00 Address VIOLA UTCA 2 8200 VESZPREM See on map Region Dunántúl Közép-Dunántúl Veszprém Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data UNIVERSITAET BERN Switzerland EU contribution € 221 594,00 Address HOCHSCHULSTRASSE 6 3012 Bern See on map Region Schweiz/Suisse/Svizzera Espace Mittelland Bern / Berne Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Total cost No data UNIVERSITAET ULM Germany EU contribution € 85 487,05 Address HELMHOLTZSTRASSE 16 89081 Ulm See on map Region Baden-Württemberg Tübingen Ulm, Stadtkreis Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Total cost No data
